Targeted Therapies in CLL: Monotherapy Versus Combination Approaches

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chemoimmunotherapy has improved chronic lymphocytic leukemia (CLL) outcomes but is not curative and has significant relapse rates.
• Novel targeted therapies offer increased response rates and reduced toxicity, particularly for high-risk CLL.
• Current CLL treatment aims for deep, durable, minimal residual disease (MRD)-negative remissions to allow for treatment-free intervals.

Purpose of the Study:

• To review recent clinical trial results and ongoing investigations in CLL therapy.
• To discuss the implications of novel agents and combination regimens for the future of CLL treatment.
• To evaluate strategies for achieving MRD-negative remissions in CLL patients.

Main Methods:

• Review of large clinical trials evaluating novel therapies in CLL.
• Analysis of data from studies on small-molecule inhibitors (e.g., ibrutinib, idelalisib, venetoclax).
• Consideration of emerging treatments like chimeric antigen receptor-T cells for refractory CLL.

Main Results:

• Novel therapies, including small-molecule inhibitors, are effective as monotherapy in CLL.
• Combining novel agents or chemoimmunotherapy may increase MRD-negative remission rates and delay resistance.
• Chimeric antigen receptor-T cells present a potential new avenue for heavily refractory CLL.

Conclusions:

• Optimizing drug combinations is crucial for various CLL patient subgroups.
• Future CLL therapy will likely involve targeted agents and potentially immunotherapy combinations.
• Achieving sustained MRD-negative remissions is a key goal for future CLL treatment strategies.